Ization, J.R.-M., A.B., M.F. and R.d.l.T.; methodology, J.R.-M. in addition to a.B.; software, A.B.; validation,

Ization, J.R.-M., A.B., M.F. and R.d.l.T.; methodology, J.R.-M. in addition to a.B.; software, A.B.; validation, J.R.-M., A.B., A.G.-G. and O.J.P.; formal analysis, J.R.-M. and a.B.; data curation, J.R.-M., A.B. and a.G.-G.; writing–original draft preparation, J.R.-M., A.B. and G.S.; writing–review and editing, J.R.-M., A.B., G.S., L.E., A.G.-G., O.J.P., M.F. and R.d.l.T.; visualization, A.B.; supervision, O.J.P., M.F. and R.d.l.T.; funding acquisition, R.d.l.T. All authors have read and agreed towards the published version in the manuscript. Funding: This study was funded by the Instituto de Salud Carlos III (PI14/00072) and by grants from DIUE of Generalitat de Catalunya (2107 SGR 138). CIBER de Fisiopatolog de la Obesidad y Bestatin site Nutrici (PF-06873600 siteCDK https://www.medchemexpress.com/s-pf-06873600.html �Ż�PF-06873600 PF-06873600 Technical Information|PF-06873600 In Vivo|PF-06873600 supplier|PF-06873600 Epigenetics} CIBEROBN) is an initiative on the ISCIII, Madrid, Spain.Antioxidants 2021, ten,11 ofInstitutional Critique Board Statement: The study was performed in accordance together with the Helsinki Declaration and approved by the regional Ethical Committee (CEIm-Parc de Salut Mar) and registered in the ClinicalTrials.gov (accessed on 20 October 2021) database (NCT02783989). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Data Availability Statement: More information can be discovered in Boronat, A.; Mateus J.; SoldevilaDomenech, N.; Guerra, M.; Rodr uez-Morat J.; Varon, C.; Mu z, D.; Barbosa, F.; Morales, J.C.; Gaedigk, A.; Langohr, K.; Covas, M.I.; P ez-Ma , C.; Fit M.; Tyndale, R.F.; de la Torre, R. Information on the endogenous conversion of tyrosol into hydroxytyrosol in humans. Data short. 2019 Nov 12;27:104787, doi:10.1016/j.dib.2019.104787. PMID: 31788516; PMCID: PMC6880089. Acknowledgments: The wine used within this study was supplied by Codorn (codorniu. com, accessed on 20 October 2021). Conflicts of Interest: The authors declare no conflict of interest.Appendix ATable A1. Retention occasions and transitions for detection of lipids working with LC-MS/MS. Lipid DAG 16:0 16:0 DAG 16:1 16:1 DAG 16:0 18:two DAG 16:0 18:1 DAG 16:0 18:0 DAG 18:two 18:2 DAG 18:0 18:2 DAG 18:1 18:1 DAG 18:0 18:1 DAG 18:0 18:0 DAG 18:0 20:4 MAG 18:1 MAG 18:2 MAG 20:4 LPC 16:0 LPC 18:0 SM (d18:1/18:0) S1P Cer 14:0 Cer 16:0 Cer 18:0 Cer 20:0 Cer 22:0 Cer 24:0 Cer 24:1 DAG 16:0 16:0-D5 DAG 16:1 16:1-D5 DAG 18:0 18:0-D5 DAG 18:1 18:1-D5 DAG 18:2 18:2-D5 DAG 20:four 20:4-D5 Cer 16:0-D7 Cer 18:0-D7 Cer 24:0-D7 Cer 24:1-D7 Retention Time (min) 1.9 1.four 1.7 two.0 two.4 1.5 2.1 two.0 two.four two.9 two.0 0.eight 0.7 0.7 0.7 0.eight 1.3 0.7 1.2 1.four 1.6 1.9 2.three 2.8 two.3 1.9 1.four 2.9 2.0 1.five 1.4 1.four 1.six two.eight 2.three Precursor m/z 586.2 582.3 610.two 612.1 614.2 634.three 638.1 638.two 640.2 642.1 662.two 357.0 355.0 379.0 496.3 523.four 731.five 300.3 510.3 538.two 566.0 594.2 622.6 650.5 648.3 591.0 587.three 647.three 643.four 639.two 687.0 545.4 573.4 657.five 655.five Item m/z 313.0 311.1 313.two 339.1 313.1 337.two 341.0 339.1 341.two 341.0 341.three 265.0 263.0 287.0 184.0 104.0 86.0 282.3 264.three 264.3 264.three 264.3 264.3 264.three 264.three 318.0 316.2 346.two 344.three 342.1 366.0 271.2 271.2 271.two 271.2 Collision Power (eV) 20 20 20 20 20 20 20 20 20 20 20 ten 10 10 20 20 50 15 30 30 30 30 30 30 30 20 20 20 20 20 20 30 30 30 30 Internal Normal DAG 16:0 16:0-D5 DAG 16:1 16:1-D5 DAG 16:0 16:0-D5 DAG 16:0 16:0-D5 DAG 16:0 16:0-D5 DAG 18:2 18:2-D5 DAG 16:0 16:0-D5 DAG 18:1 18:1-D5 DAG 18:0 18:0-D5 DAG 18:0 18:0-D5 DAG 20:4 20:4-D5 Cer 24:1-D7 DAG 18:two 18:2-D5 DAG 20:4 20:4-D5 Cer 16:0-D7 Cer 18:0-D7 Cer 24:1-D7 Cer 16:0-D7 Cer 16:0-D7 Cer 16:0-D7 Cer 18:0-D7 Cer 18:0-D7 Cer 24:0-D7 Cer 24:0-D7 Cer 24:1-D7 Acquisition System 1 1 1 1.